CA Patent

CA2021316C — Intraocular pressure reducing 11-acyl prostaglandins

Assigned to Allergan Sales LLC · Expires 2000-10-24 · 26y expired

What this patent protects

Disclosed is an intraocular pressure reducing method and composition wherein 11-acyl prostaglandins are contained in a pharmaceutically acceptable excipient for topical application to the surface of the eye.

USPTO Abstract

Disclosed is an intraocular pressure reducing method and composition wherein 11-acyl prostaglandins are contained in a pharmaceutically acceptable excipient for topical application to the surface of the eye.

Drugs covered by this patent

Patent Metadata

Patent number
CA2021316C
Jurisdiction
CA
Classification
—
Expires
2000-10-24
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Sales LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.